Megestrol acetate
- Generic Name
- Megestrol acetate
- Brand Names
- Megace
- Drug Type
- Small Molecule
- Chemical Formula
- C24H32O4
- CAS Number
- 595-33-5
- Unique Ingredient Identifier
- TJ2M0FR8ES
- Background
17-Hydroxy-6-methylpregna-3,6-diene-3,20-dione. A progestational hormone used most commonly as the acetate ester. As the acetate, it is more potent than progesterone both as a progestagen and as an ovulation inhibitor. It has also been used in the palliative treatment of breast cancer.
- Indication
For the treatment of anorexia, cachexia, or an unexplained, significant weight loss in patients with a diagnosis of acquired immunodeficiency syndrome (AIDS). Also used for the palliative management of recurrent, inoperable, or metastatic breast cancer, endometrial cancer, and prostate cancer in Canada and some other countries.
- Associated Conditions
- Anorexia, Cachexia, Inoperable Carcinoma of Breast, Inoperable Endometrial Carcinoma, Metastatic Breast Carcinoma, Recurrent Breast Carcinoma, Recurrent Endometrial Carcinoma, Significant, Unexplained Weight Loss, Metastatic Endometrial carcinoma
- Associated Therapies
- Palliative Treatment
A Study Comparing Megestrol Acetate at 800 mg/Day, and Placebo in AIDS Patients With Anorexia and Cachexia
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2007-10-02
- Lead Sponsor
- Bristol-Myers Squibb
- Registration Number
- NCT00002067
- Locations
- 🇺🇸
Dr Mark Goldstein, Los Angeles, California, United States
🇺🇸Eisenhower Med Ctr, Rancho Mirage, California, United States
🇺🇸Northwestern Univ Med School, Chicago, Illinois, United States
A Study of Megestrol Acetate in HIV-Infected Children
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Gamma Project - ACTU
- Target Recruit Count
- 25
- Registration Number
- NCT00002182
- Locations
- 🇵🇷
Univ of Puerto Rico / Med Science Campus, San Juan, Puerto Rico
A Study of Megestrol Acetate Alone or in Combination With Testosterone Enanthate Drug in the Treatment of HIV-Associated Weight Loss
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-01
- Target Recruit Count
- 80
- Registration Number
- NCT00001079
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Ctr., New York, New York, United States
🇺🇸USC CRS, Los Angeles, California, United States
🇺🇸UCLA CARE Center CRS, Los Angeles, California, United States
A Study of Different Doses of Megestrol Acetate in Patients With AIDS Who Have Anorexia and Malnutrition
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2007-10-02
- Lead Sponsor
- Bristol-Myers Squibb
- Registration Number
- NCT00002300
- Locations
- 🇺🇸
George Washington Univ Med Ctr, Washington, District of Columbia, United States
🇺🇸Denver Public Health Dept, Denver, Colorado, United States
🇺🇸Dr Stephen J Gabin Jr, Los Angeles, California, United States
The Safety and Effectiveness of Megace in HIV-Infected Women
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2007-10-02
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 40
- Registration Number
- NCT00002345
- Locations
- 🇺🇸
Yale Univ Med School, New Haven, Connecticut, United States
🇺🇸Georgetown Univ Med Ctr, Washington, District of Columbia, United States
🇺🇸Univ of California - Davis Med Ctr / CARES, Sacramento, California, United States
A Phase I/II Study to Evaluate Single Agent and Combination Therapy With Megestrol Acetate and Dronabinol for the Treatment of HIV-Wasting Syndrome
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2008-08-25
- Target Recruit Count
- 56
- Registration Number
- NCT00000737
- Locations
- 🇺🇸
Denver Public Health Dept, Denver, Colorado, United States
🇺🇸Univ of Illinois, Chicago, Illinois, United States
🇺🇸Univ of Kansas School of Medicine, Wichita, Kansas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.